Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells.

Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells.
复制标题

DOI:
10.1016/j.canlet.2009.02.035
复制
发表时间:
2009-08-18
期刊:
影响因子:
9.7
通讯作者:
Welch, Danny R.
Welch, Danny R.
中科院分区:
医学1区
文献类型:
--
作者:
Vaidya, Kedar S.;Sanchez, Jesus J.;Kim, Eun Lim;Welch, Danny R.

文献摘要

参考文献

被引文献

相似文献

乳腺癌转移抑制因子1(BRMS 1)属于一种不断扩展的称为转移抑制因子的蛋白质类别,其表现出体内转移抑制,同时仍允许原位肿瘤生长。由于BRMS 1降低了与化疗耐药有关的多种介质(NF-κB、AKT、EGFR)的表达或功能,因此我们询问表达BRMS 1的乳腺癌细胞是否可以在暴露于抑制与BRMS 1相同的细胞介质中的一些的常用治疗剂后被致敏。在这份报告中,我们证明了乳腺癌细胞的化学敏感性在BRMS 1的存在下得到保留。此外,BRMS 1不改变AKT同种型或PTEN的表达,其与对常见药物的化学抗性有关。总的来说,我们的数据与两种不同的转移性乳腺癌细胞系表明,BRMS 1表达状态可能不会干扰常用的化疗药物在实体瘤,如乳腺癌的管理的反应。由于肿瘤蛋白表达分析越来越多地指导治疗决策,我们的数据可能在疾病管理中具有临床益处,包括在治疗开始前分析BRMS 1表达。
The Breast Cancer Metastasis Suppressor 1 (BRMS1) belongs to an expanding category of proteins called metastasis suppressors that demonstrate in vivo metastasis suppression while still allowing growth of the orthotopic tumor. Since BRMS1 decreases either the expression or function of multiple mediators implicated in resistance to chemotherapy (NF-κB, AKT, EGFR), we asked whether breast carcinoma cells expressing BRMS1 could be sensitized upon exposure to commonly used therapeutic agents that inhibit some of these same cellular mediators as BRMS1. In this report, we demonstrate that chemosensitivity of breast cancer cells is preserved in the presence of BRMS1. Further, BRMS1 does not change expression of AKT isoforms or PTEN, implicated in chemoresistance to common drug agents. Overall, our data with two different metastatic breast cancer cell lines indicates that BRMS1 expression status may not interfere with the response to commonly used chemotherapeutic agents in the management of solid tumors such as breast cancer. Since tumor protein expression analysis increasingly guides therapy decisions, our data may be of clinical benefit in disease management including profiling for BRMS1 expression before start of therapy.
DOI: 10.1186/1476-4598-6-6
发表时间: 2007-01-16
期刊: Molecular cancer
影响因子: 37.3
作者:
Samant RS;Clark DW;Fillmore RA;Cicek M;Metge BJ;Chandramouli KH;Chambers AF;Casey G;Welch DR;Shevde LA
通讯作者: Shevde LA
DOI: 10.1002/ijc.23542
发表时间: 2008-08-01
影响因子: 6.4
作者:
Hedley, Benjamin D.;Welch, Danny R.;Chambers, Ann F.
通讯作者: Chambers, Ann F.
DOI: 10.1074/jbc.m307969200
发表时间: 2004-01-09
影响因子: 4.8
作者:
Meehan, WJ;Samant, RS;Welch, DR
通讯作者: Welch, DR
DOI: 10.1074/jbc.m112210200
发表时间: 2002-03-08
影响因子: 4.8
作者:
Dhawan, P;Richmond, A
通讯作者: Richmond, A
DOI: 10.1158/1078-0432.ccr-06-0635
发表时间: 2006-11-15
影响因子: 11.5
作者:
Hicks, David G.;Yoder, Brian J.;Casey, Graham
通讯作者: Casey, Graham